Loading patent…
AssigneeKyungpook National University Industry-Academic Cooperation Foundation
InventorsMoon Chang Baek, Pyong Gon Moon, Yong Lim Kim
Estimating the term…
Disclosed is the development of a protein used as a biomarker for diagnosing IgA nephropathy and TGBM (thin-glomerular-basement-membrane) using urine through a target proteomics method. The disclosed development relates to a diagnosis biomarker protein and a kit for diagnosing IgA nephropathy and TGBM and predicting progress of the nephropathy in advance using the protein. The protein level is increased or decreased in urine from a patient with IgA nephropathy or TGBM nephropathy compared to urine from a normal patient. According to the disclosed development, the degree of the disease can be grasped by detecting IgA nephropathy and TGBM, enabling early diagnosis and confirming progress from the patient's urine. In addition, a monoclonal antibody produced based on the diagnosis biomarker protein can be used for an immunoassay kit (ELISA, antibody coated tube test, lateral-flow test, potable biosensor). As well, the monoclonal antibody is used in early diagnosis and progress detection of IgA nephropathy and development of a novel drug for the purpose of treatment.
A biomarker composition for diagnosing IgA nephropathy and TGBM nephropathy, the biomarker composition comprising, as an active component, three or more proteins selected from the group including proteins increased/decreased in urine of IgA nephropathy patients and thin-glomerular-basement-membrane (TGBM) nephropathy patients compared to those in normal people, wherein the proteins increased/decreased in the IgA nephropathy patients and the TGBM nephropathy patients comprise:
A biomarker composition for diagnosing TGBM nephropathy, the biomarker composition comprising, as an active component, three or more proteins selected from the group including proteins increased in urine of TGBM nephropathy patients compared to those in normal people, wherein the proteins increased in the TGBM nephropathy patients comprise:
A biomarker composition for diagnosing IgA nephropathy, the biomarker composition comprising, as an active component, three or more proteins selected from the group including proteins increased in urine of IgA nephropathy patients compared to those in normal people, wherein the proteins increased in the IgA nephropathy patients comprise:
Dependencies are inferred from the claim text.